Toward an Epidemiology of Refractory Migraine: Current Knowledge and Issues for Future Research

Authors

  • Richard B. Lipton MD,

    1. From the Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA (R.B. Lipton and M.E. Bigal); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA (R.B. Lipton); The Montefiore Headache Center, Bronx, NY, USA (R.B. Lipton); Global Director for Scientific Affairs, Division of Neuroscience, Merck Research Laboratories, Whitehouse Station, NJ, USA (M.E. Bigal).
    Search for more papers by this author
  • Marcelo E. Bigal MD, PhD

    1. From the Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA (R.B. Lipton and M.E. Bigal); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA (R.B. Lipton); The Montefiore Headache Center, Bronx, NY, USA (R.B. Lipton); Global Director for Scientific Affairs, Division of Neuroscience, Merck Research Laboratories, Whitehouse Station, NJ, USA (M.E. Bigal).
    Search for more papers by this author

  • Conflict of Interest: Dr. Bigal is an employee of Merck Research Laboratories.

R.B. Lipton, Department of Neurology, Albert Einstein College of Medicine, 1165 Morris Park Avenue, Bronx, NY 10461, USA.

Abstract

The proposed definitions for refractory migraine (RM) and refractory chronic migraine (R-CM) comprise 5 key components that must be operationalized for epidemiologic research. Persons with RM or R-CM must meet the second edition of the International Classification of Headache Disorders criteria for migraine or chronic migraine. They must experience significant interference with function or quality of life due to headaches. This interference must be present despite adequate treatment in 3 domains: modification of triggers and lifestyle factors, acute medication, and preventive medicines. The epidemiologic data which address these 5 components will be reviewed herein though specifically designed studies will be required to fully explore RM and R-CM. In addition, 2 “modifiers” of RM and R-CM have been proposed; one addresses medication overuse and the other considers disability based on a Migraine Disability Assessment score of 11 or greater. The epidemiology of these modifiers is discussed.

Ancillary